RADIUS is ready for an upward rally after being beaten down
RADIUS is one of my most promising stock at the moment.
-From a micro-technical point of view, we see signs of trend reversal.
Two morning stars and two head & shoulders patterns (switch time frames) recently.
-From a macro-technical and fundamental perspective, there are several reasons that augment the reversal probability:
RADIUS was beaten down (too much).
It is lower than months and even years ago while, at the same time, having stronger fundamentals.
Radius is still in the innovation race as it entered in the Phase III of a new osteoporosis treatment (and IMO it is pretty incredible that the stock didn't move the day it was announced!)
Source: globenewswire.com/news-release/2020/05/27/2039144/0/en/Pivotal-Phase-III-trial-of-abaloparatide-SC-in-Japanese-women-and-men-with-osteoporosis-achieves-primary-endpoint.html
-From an even more macro perspective, the stock should be fueled by investors that bet on stocks that provide products that will be more demanded by an ageing population (osteoporosis).
-From a micro-technical point of view, we see signs of trend reversal.
Two morning stars and two head & shoulders patterns (switch time frames) recently.
-From a macro-technical and fundamental perspective, there are several reasons that augment the reversal probability:
RADIUS was beaten down (too much).
It is lower than months and even years ago while, at the same time, having stronger fundamentals.
Radius is still in the innovation race as it entered in the Phase III of a new osteoporosis treatment (and IMO it is pretty incredible that the stock didn't move the day it was announced!)
Source: globenewswire.com/news-release/2020/05/27/2039144/0/en/Pivotal-Phase-III-trial-of-abaloparatide-SC-in-Japanese-women-and-men-with-osteoporosis-achieves-primary-endpoint.html
-From an even more macro perspective, the stock should be fueled by investors that bet on stocks that provide products that will be more demanded by an ageing population (osteoporosis).
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.